A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subtype-Selective JAK Inhibitors for Preservation of Pancreatic Cell Function in Newly Diagnosed Type 1 Diabetes Mellitus
Trial Net JAKPOT Type 1 Diabetes (T1D)
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Enrolling: Male and Female Patients
Study Length: 2 Years
IRB Number: AAAU7453
U.S. Govt. ID: NCT05743244
Contact: Kaisha Mofford: 212-851-5512 / km3870@cumc.columbia.edu
Additional Study Information: The purpose of this study is testing two different Janus kinase (JAK) inhibitors, Abrocitinib and Ritlecitinib, to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D). Researchers believe JAK inhibitors may be able to calm the immune system's attack on insulin producing beta cells in the pancreas.
Jacqueline Lonier, MD
Do You Qualify?
Are you between the ages of 12-35? Yes No
Have you been diagnosed with type 1 diabetes within the last 100 days? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Kaisha Mofford